Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
Qurient Co Ltd 1115180:
QURIENT ANNOUNCES DOSING OF FIRST PATIENT IN Q901 PHASE 1/2 CLINICAL STUDY FOR THE TREATMENT OF PATIENTS WITH SOLID TUMORS